PHASE I OF CPT-11 USING EVERY OTHER WEEK DOSING SCHEDULE

CPT-11 的第一阶段采用每隔一周的给药方案

• 批准号: 5223261
• 负责人: MACE L ROTHENBERG
• 金额: --
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/5223261
• 关键词: antineoplastics; camptothecin; clinical research; clinical trial phase I; dosage; drug administration rate /duration; drug screening /evaluation; human subject; pharmacokinetics; prodrugs

The objectives of this phase I study are to determine the MTD of irinotecan when administered every other week to patients with advanced solid tumor malignancies, to evaluate the qualitative and quantitative toxicities of irinotecan on an every-other-week schedule, and to obtain a pharmacokinetic profile of irinotecan and its active metabolite, SN-38 at the doses used on an every-other-week schedule.

这项第一阶段研究的目标是确定 伊立替康每隔一周给晚期糖尿病患者一次 实体瘤恶性程度的定性和定量评价 伊立替康的毒性，每隔一周进行一次，并获得 伊立替康及其活性代谢产物SN-38的药动学研究 按照每隔一周的日程表使用的剂量。